Investor Relations

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Recent Releases

Dec 04, 2023
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Dec 04, 2023
EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints
Nov 16, 2023
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 01, 2023
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments
Oct 31, 2023
EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023

Stern Investor Relations
p. 212.362.1200

Amy Phillips
p. 412.327.9499